Data from Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Receiving First-line Osimertinib
Year: 2026
Type: other
Abstract: Purpose: With rapidly expanding treatment options for patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC), identifying biomarkers that may assist in treatment selection is critical. The impact of EGFR amplification (EGFRAMP) on outcomes to osimertinib is currently unknown. Experimental Design: Patients with metastatic EGFR-mutated NSCLC who received first-line osimertinib and had undergone baseline next-generation sequencing (NGS) that included assessment of EGFRAMP were included. EGFRAMP was defined as an EGFR copy number (CN) ≥6. Results: Among 473 patients, 81 (17.1%) had EGFRAMP. Compared with patients with non-amplified EGFR (EGFRNon-AMP; n = 392), they frequently had TP53 comutations (80% vs. 55.4%, P < 0.001) and brain (50.6% vs. 34.3%, P = 0.008), liver (25.9% vs. 13.5%, P = 0.009), and bone (65.4% vs. 51.3%, P = 0.028) metastases. When treated with osimertinib, patients with EGFRAMP achieved a similar objective response rate (88% vs. 83%, P = 0.23) but shorter median progression-free survival [PFS; 11.6 vs. 19 months, hazard ratio (HR), 1.77; P < 0.0001] and overall survival (OS; 34 vs. 40.1 months; HR, 1.40; P = 0.040). EGFRAMP was consistently associated with worse PFS regardless of TP53 comutations; however, EGFRAMP was associated with worse PFS and OS in patients with EGFR exon 19 deletion, but not in those with EGFR L858R. Within EGFRAMP cases, a higher EGFR CN and the amplification of the mutant allele, as opposed to wild-type amplification, correlated with inferior outcomes. Among patients reassessed with NGS after osimertinib resistance (n = 113), those with baseline EGFRAMP more frequently showed acquired MET alterations (29% vs. 12%, P = 0.04). Conclusions: EGFRAMP correlates with distinct characteristics and worse outcomes to osimertinib monotherapy among patients with EGFR-mutated NSCLC.
Authors: Alessandro Di Federico, Federica Pecci, Mark Jeng, Marianna Peroni, Daniele Marinelli, Alessandro Leonetti, Sara Stumpo, Francesco Mantuano, Irene Zannini, Eleonora Gariazzo, Maisam Makarem, Amanda Pupo, Francesca Lo Bianco, Andrea De Giglio, Dario de Biase, Annalisa Altimari, Elisa Gruppioni, Roberta Minari, Michela Verzè, Matteo Repetto, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Lorenza Landi, Maristella Giammaruco, Stefano Scalera, Laura Cipriani, Marcello Maugeri-Saccà, Nicola Calonaci, Giulio Caravagna, Biagio Ricciuti, Lynette M. Sholl, Soo Ryum Yang, Jaclyn LoPiccolo, Julia K. Rotow, Mark M. Awad, Federico Cappuzzo, Marcello Tiseo, Helena A. Yu, Pasi A. Jänne, Andrea Ardizzoni
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7213337796
Cites:
Cited by:
Related to: